8-K Announcements
6Material company update
Jan 6, 2026·SEC
Material company update
Nov 14, 2025·SEC
Material company update
Nov 13, 2025·SEC
Mersana Therapeutics, Inc.(MRSN)Earnings, Financials & Key Ratios
MRSN•NASDAQ
$29.08
$145M mkt cap·Price updated Apr 24, 2026
AboutMersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen development candidate. It has a strategic research and development partnerships with Merck KGaA and Asana BioSciences, LLC for the development of ADC product candidates utilizing Fleximer. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$40M+9.9%
- EBITDA-$72M+57.7%
- Net Income-$69M+59.7%
- EPS (Diluted)-14.12+61.8%
- Gross Margin100%
- EBITDA Margin-177.07%+61.5%
- Operating Margin-181.09%+61.0%
- Net Margin-170.86%+63.3%
- ROE-505.14%-89.7%
- Interest Coverage-18.93+54.9%
MRSN Key Insights
Mersana Therapeutics, Inc. (MRSN) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Momentum leader: RS Rating 97 (top 3%)
- ✓Trading near 52-week high
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
MRSN Price & Volume
Mersana Therapeutics, Inc. (MRSN) stock price & volume — 10-year historical chart
Loading chart...
MRSN Growth Metrics
Mersana Therapeutics, Inc. (MRSN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-0.78%
3 Years880.21%
TTM-4.76%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM6.08%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM8.03%
Return on Capital
10 Years-113.61%
5 Years-84.96%
3 Years-81.95%
Last Year-59.96%
MRSN Recent Earnings
Mersana Therapeutics, Inc. (MRSN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
Mar 2, 2026EPS
$2.75
Est $3.05
+10.0%
Revenue
—
Est $5M
Q4 2025
Nov 14, 2025EPS
$1.51
Est $1.44
-4.9%
Revenue
$11M
Est $2M
+442.3%
Q3 2025
Aug 13, 2025EPS
$4.08
Est $3.75
-8.8%
Revenue
$3M
Est $11M
-71.2%
Q2 2025
May 15, 2025EPS
$4.75
Est $5.25
+9.5%
Revenue
$3M
Est $6M
-55.0%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 2, 2026 | $2.75vs $3.05+10.0% | —vs $5M |
| Q4 2025 | Nov 14, 2025 | $1.51vs $1.44-4.9% | $11Mvs $2M+442.3% |
| Q3 2025 | Aug 13, 2025 | $4.08vs $3.75-8.8% | $3Mvs $11M-71.2% |
| Q2 2025 | May 15, 2025 | $4.75vs $5.25+9.5% | $3Mvs $6M-55.0% |
Based on last 12 quarters of dataView full earnings history →
MRSN Peer Comparison
Mersana Therapeutics, Inc. (MRSN) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.62B | 26.00 | -7.90 | -4.26% | -156.36% | -68.97% | 0.16 | |
 SNDX | 1.82B | 20.65 | -6.28 | 6.28% | -112.01% | -256.66% | 5.36 | |
 AGEN | 137.4M | 3.89 | -1144.12 | 10.37% | 0.1% | |||
 TGTX | 6.7B | 41.97 | 15.15 | 87.32% | 65.95% | 87.36% | 0.40 | |
 NKTR | 1.67B | 85.09 | -8.75 | -43.89% | -192.87% | -356.81% | 0.95 | |
 ARVN | 656.24M | 10.26 | -8.02 | -0.3% | -30.77% | -14.25% | 0.02 | |
 BCAB | 5.29M | 4.50 | -0.09 | -81.82% | -29.8% | |||
 BYSI | 65.73M | 1.63 | -5.82 |
Compare MRSN vs Peers
Mersana Therapeutics, Inc. (MRSN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
MRSN Income Statement
Mersana Therapeutics, Inc. (MRSN) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 25.17M | 17.55M | 10.59M | 42.12M | 828K | 43K | 26.58M | 36.85M | 40.5M | 33.18M |
| Revenue Growth % | 142.99% | -30.3% | -39.62% | 297.61% | -98.03% | -94.81% | 61716.28% | 38.65% | 9.88% | -4.76% |
| Cost of Goods Sold | 32.01M | 928K | 59.91M | 0 | 67.04M | 0 | 0 | 0 | 0 | 287K |
| COGS % of Revenue | 127.16% | 5.29% | 565.56% | - | 8096.14% | - | - | - | - | - |
| Gross Profit | -6.84M▲ 0% | 16.62M▲ 343.0% | -49.32M▼ 396.8% | 42.12M▲ 185.4% | -66.21M▼ 257.2% | 43K▲ 100.1% | 26.58M▲ 61716.3% | 36.85M▲ 38.7% | 40.5M▲ 9.9% | 32.89M▲ 0% |
| Gross Margin % | -27.16% | 94.71% | -465.56% | 100% | -7996.14% | 100% | 100% | 100% | 100% | 99.13% |
| Gross Profit Growth % | 37.81% | 343.05% | -396.81% | 185.41% | -257.18% | 100.06% | 61716.28% | 38.65% | 9.88% | - |
| Operating Expenses | 38.99M | 57.16M | 76.25M | 72.32M | 88.94M | 168.9M | 230.35M | 207.81M | 113.83M | 100.27M |
| OpEx % of Revenue | 154.91% | 325.8% | 719.74% | 171.69% | 10741.3% | 392793.02% | 866.59% | 563.86% | 281.09% | - |
| Selling, General & Admin | 6.98M | 10.46M | 16.33M | 17.28M | 21.9M | 36.89M | 56.96M | 59.54M | 40.81M | 31.53M |
| SG&A % of Revenue | 27.75% | 59.63% | 154.18% | 41.03% | 2645.17% | 85786.05% | 214.3% | 161.56% | 100.78% | - |
| Research & Development | 32.01M | 46.7M | 59.91M | 55.04M | 67.04M | 132.01M | 173.38M | 148.27M | 73.02M | 69.03M |
| R&D % of Revenue | 127.16% | 266.17% | 565.56% | 130.67% | 8096.14% | 307006.98% | 652.29% | 402.3% | 180.31% | - |
| Other Operating Expenses | 0 | 0 | 1.4M | 0 | 0 | 0 | 0 | 0 | 0 | -287K |
| Operating Income | -13.82M▲ 0% | -39.62M▼ 186.6% | -65.66M▼ 65.7% | -30.2M▲ 54.0% | -155.15M▼ 413.7% | -168.86M▼ 8.8% | -203.77M▼ 20.7% | -170.96M▲ 16.1% | -73.34M▲ 57.1% | -67.38M▲ 0% |
| Operating Margin % | -54.91% | -225.8% | -619.74% | -71.69% | -18737.44% | -392693.02% | -766.59% | -463.86% | -181.09% | -203.06% |
| Operating Income Growth % | 15.42% | -186.64% | -65.72% | 54% | -413.73% | -8.84% | -20.67% | 16.1% | 57.1% | - |
| EBITDA | -13.17M | -38.69M | -64.4M | -28.95M | -154.14M | -168M | -202.84M | -169.44M | -71.71M | -66.29M |
| EBITDA Margin % | -52.31% | -220.51% | -607.87% | -68.74% | -18615.46% | -390704.65% | -763.1% | -459.75% | -177.07% | -199.79% |
| EBITDA Growth % | 17.94% | -193.86% | -66.45% | 55.04% | -432.33% | -9% | -20.74% | 16.47% | 57.68% | 14.77% |
| D&A (Non-Cash Add-back) | 655K | 928K | 1.26M | 1.25M | 1.01M | 855K | 927K | 1.52M | 1.63M | 1.09M |
| EBIT | -13.82M | -38.71M | -64.26M | -27.97M | -88.11M | -168.79M | -200.88M | -167.6M | -64.9M | -67.33M |
| Net Interest Income | 121K | 910K | 1.4M | 1.99M | 65K | -1.2M | -445K | 8M | 4.56M | 1.43M |
| Interest Income | 121K | 910K | 1.4M | 2.23M | 424K | 65K | 2.88M | 12.07M | 8.44M | 4.17M |
| Interest Expense | 0 | 0 | 0 | 234K | 359K | 1.27M | 3.33M | 4.07M | 3.87M | 2.75M |
| Other Income/Expense | 121K | 910K | 1.4M | 1.99M | 67.1M | -1.2M | -445K | -713K | 4.56M | -2.71M |
| Pretax Income | -13.7M▲ 0% | -38.71M▼ 182.5% | -64.26M▼ 66.0% | -28.21M▲ 56.1% | -88.05M▼ 212.1% | -170.06M▼ 93.2% | -204.21M▼ 20.1% | -171.67M▲ 15.9% | -68.77M▲ 59.9% | -70.08M▲ 0% |
| Pretax Margin % | -54.43% | -220.62% | -606.54% | -66.97% | -10633.45% | -395488.37% | -768.26% | -465.8% | -169.82% | -211.21% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | -0.61% | 0% |
| Net Income | -13.7M▲ 0% | -38.71M▼ 182.5% | -64.26M▼ 66.0% | -28.21M▲ 56.1% | -88.05M▼ 212.1% | -170.06M▼ 93.2% | -204.21M▼ 20.1% | -171.67M▲ 15.9% | -69.19M▲ 59.7% | -70.08M▲ 0% |
| Net Margin % | -54.43% | -220.62% | -606.54% | -66.97% | -10633.45% | -395488.37% | -768.26% | -465.8% | -170.86% | -211.21% |
| Net Income Growth % | 16.61% | -182.53% | -66.01% | 56.1% | -212.13% | -93.15% | -20.08% | 15.94% | 59.69% | 6.08% |
| Net Income (Continuing) | -13.7M | -38.71M | -64.26M | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M | -69.19M | -70.08M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -19.58▲ 0% | -42.95▼ 119.4% | -69.75▼ 62.4% | -16.21▲ 76.8% | -35.80▼ 120.9% | -60.24▼ 68.3% | -54.51▲ 9.5% | -36.96▲ 32.2% | -14.12▲ 61.8% | -14.05▲ 0% |
| EPS Growth % | 16.61% | -119.36% | -62.4% | 76.76% | -120.85% | -68.27% | 9.51% | 32.2% | 61.8% | 8.03% |
| EPS (Basic) | -19.58 | -43.00 | -69.75 | -16.25 | -35.80 | -60.24 | -54.51 | -36.96 | -14.12 | - |
| Diluted Shares Outstanding | 699.73K | 901.17K | 921.29K | 1.74M | 2.46M | 2.82M | 3.75M | 4.64M | 4.9M | 4.99M |
| Basic Shares Outstanding | 699.73K | 900.14K | 921.29K | 1.74M | 2.46M | 2.82M | 3.75M | 4.64M | 4.9M | 4.99M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
MRSN Balance Sheet
Mersana Therapeutics, Inc. (MRSN) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 102.17M | 117.54M | 70.13M | 101.33M | 258.58M | 188.9M | 319.22M | 214.06M | 136.9M | 59.99M |
| Cash & Short-Term Investments | 100.3M | 114.73M | 70.13M | 99.79M | 255.09M | 177.95M | 280.71M | 209.08M | 134.62M | 56.39M |
| Cash Only | 100.3M | 26.59M | 59.63M | 62.35M | 255.09M | 177.95M | 128.88M | 174.56M | 107.75M | 56.39M |
| Short-Term Investments | 0 | 88.14M | 10.5M | 37.44M | 0 | 0 | 151.83M | 34.52M | 26.87M | 0 |
| Accounts Receivable | 1.05M | 784K | 459K | 0 | 0 | 0 | 30M | 0 | 0 | 168K |
| Days Sales Outstanding | 15.24 | 16.31 | 15.81 | - | - | - | 411.95 | - | - | 1.19 |
| Inventory | 0 | 0 | -4.17M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 0 | 2.02M | 3.71M | 1.54M | 0 | 10.95M | 8.51M | 4.97M | 2.28M | 3.43M |
| Total Non-Current Assets | 2.91M | 13.17M | 8.37M | 6.21M | 14.82M | 17.21M | 15.12M | 12M | 7.76M | 2.7M |
| Property, Plant & Equipment | 2.48M | 2.32M | 2.69M | 4.76M | 12.67M | 14.86M | 14.46M | 11.53M | 6.78M | 2.2M |
| Fixed Asset Turnover | 10.14x | 7.57x | 3.93x | 8.85x | 0.07x | 0.00x | 1.84x | 3.20x | 5.97x | 7.16x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 321K | 10.48M | 371K | 321K | 321 | 478K | 0 | 0 | 0 | 657K |
| Other Non-Current Assets | 110K | 371K | 5.31M | 1.13M | 2.15M | 1.88M | 661K | 478K | 978K | 1.98M |
| Total Assets | 105.09M▲ 0% | 130.72M▲ 24.4% | 78.5M▼ 39.9% | 107.54M▲ 37.0% | 273.4M▲ 154.2% | 206.11M▼ 24.6% | 334.34M▲ 62.2% | 226.06M▼ 32.4% | 144.66M▼ 36.0% | 62.69M▲ 0% |
| Asset Turnover | 0.24x | 0.13x | 0.13x | 0.39x | 0.00x | 0.00x | 0.08x | 0.16x | 0.28x | 0.33x |
| Asset Growth % | 629.31% | 24.39% | -39.94% | 36.99% | 154.23% | -24.61% | 62.21% | -32.39% | -36.01% | -195.12% |
| Total Current Liabilities | 28.39M | 31.88M | 69.42M | 24.07M | 30M | 47.52M | 91.53M | 63.64M | 62.46M | 43.27M |
| Accounts Payable | 2.07M | 3.07M | 10.73M | 7.3M | 8.34M | 12.32M | 13.95M | 7.32M | 4.33M | 2.39M |
| Days Payables Outstanding | 23.58 | 1.21K | 65.35 | - | 45.41 | - | - | - | - | 4.46K |
| Short-Term Debt | 0 | 0 | 0 | 667K | 93K | 0 | 0 | 2.08M | 12.5M | 2.29M |
| Deferred Revenue (Current) | 22.73M | 21.64M | 46.2M | 4.82M | 3.99M | 3.94M | 30.61M | 28.15M | 22.17M | 89.84M |
| Other Current Liabilities | 1.31M | 4.13M | 9.46M | 5.04M | 10.83M | 21.64M | 990K | 13.88M | 12.26M | 14.81M |
| Current Ratio | 3.60x | 3.69x | 1.01x | 4.21x | 8.62x | 3.97x | 3.49x | 3.36x | 2.19x | 2.19x |
| Quick Ratio | 3.60x | 3.69x | 1.07x | 4.21x | 8.62x | 3.97x | 3.49x | 3.36x | 2.19x | 2.19x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -4.46K |
| Total Non-Current Liabilities | 132.32M | 28.84M | 282K | 5.15M | 15.31M | 36.85M | 150.75M | 125.52M | 91.71M | 78.95M |
| Long-Term Debt | 0 | 0 | 0 | 4.2M | 4.98M | 24.63M | 24.93M | 23.15M | 10.95M | 0 |
| Capital Lease Obligations | 0 | 0 | 0 | 677K | 10.16M | 11.25M | 8.57M | 5.2M | 1.29M | 1.55M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 94.75M | 67K | 282K | 275K | 174K | 974K | 203K | 1K | 8K | 78.96M |
| Total Liabilities | 160.71M | 60.72M | 69.71M | 29.22M | 45.31M | 84.37M | 242.28M | 189.16M | 154.17M | 122.22M |
| Total Debt | 0 | 0 | 0 | 7.76M | 16.66M | 38.18M | 36.3M | 33.83M | 28.6M | 2.29M |
| Net Debt | -100.3M | -26.59M | -59.63M | -54.59M | -238.43M | -139.77M | -92.58M | -140.73M | -79.15M | -54.1M |
| Debt / Equity | - | - | - | 0.10x | 0.07x | 0.31x | 0.39x | 0.92x | - | -0.04x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.03x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.82x |
| Interest Coverage | - | - | - | -129.06x | -432.16x | -133.27x | -61.23x | -41.97x | -18.93x | -24.52x |
| Total Equity | -55.62M▲ 0% | 69.99M▲ 225.8% | 8.79M▼ 87.4% | 78.32M▲ 790.5% | 228.09M▲ 191.2% | 121.74M▼ 46.6% | 92.06M▼ 24.4% | 36.9M▼ 59.9% | -9.51M▼ 125.8% | -59.54M▲ 0% |
| Equity Growth % | -30.28% | 225.85% | -87.43% | 790.48% | 191.23% | -46.63% | -24.38% | -59.91% | -125.77% | -6842.33% |
| Book Value per Share | -79.49 | 77.67 | 9.55 | 45.02 | 92.74 | 43.12 | 24.57 | 7.95 | -1.94 | -11.94 |
| Total Shareholders' Equity | -55.62M | 69.99M | 8.79M | 78.32M | 228.09M | 121.74M | 92.06M | 36.9M | -9.51M | -59.54M |
| Common Stock | 1K | 3K | 3K | 5K | 7K | 7K | 11K | 12K | 12K | 0 |
| Retained Earnings | -59.17M | -97.88M | -164.17M | -192.37M | -280.42M | -450.48M | -654.69M | -826.36M | -895.55M | -951.52M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -4.21M | -149K | -8K | 25K | 0 | 0 | -152K | 11K | 10K | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
MRSN Cash Flow Statement
Mersana Therapeutics, Inc. (MRSN) cash flow — operating, investing & free cash flow history
| Line item | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 31.59M | -42.68M | -55.22M | -67.74M | -74.7M | -139.99M | -49.36M | -168.88M | -82.34M | -82.34M |
| Operating CF Margin % | 125.49% | -243.25% | -521.2% | -160.82% | -9021.26% | -325553.49% | -185.71% | -458.23% | -203.32% | - |
| Operating CF Growth % | 427.81% | -235.11% | -29.38% | -22.69% | -10.26% | -87.41% | 64.74% | -242.12% | 51.24% | 109.34% |
| Net Income | -13.7M | -38.71M | -64.26M | -28.21M | -88.05M | -170.06M | -204.21M | -171.67M | -69.19M | -70.08M |
| Depreciation & Amortization | 655K | 928K | 1.26M | 1.25M | 1.01M | 855K | 927K | 1.52M | 1.63M | 1.09M |
| Stock-Based Compensation | 668K | 1.42M | 3.88M | 4.87M | 7.17M | 18.41M | 21.52M | 21.14M | 16.46M | 9.26M |
| Deferred Taxes | -102K | -134K | -386K | -222K | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 102K | -159K | 110K | 103K | 62K | 723K | -699K | -1.1M | -496K | 3.83M |
| Working Capital Changes | 43.97M | -6.03M | 4.18M | -45.53M | 5.11M | 10.09M | 133.1M | -18.76M | -30.74M | -18.47M |
| Change in Receivables | -411K | 267K | 325K | 459K | 0 | 0 | -30M | 30M | 0 | 1.1M |
| Change in Inventory | 1.42M | 2.42M | 2.61M | -1.5M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | -325K | 1.33M | 7.38M | -3.11M | 942K | 483K | 947K | -6.08M | -2.86M | 360K |
| Cash from Investing | -1.08M | -99.62M | 87.19M | -27.29M | 37.03M | -648K | -152.72M | 119.88M | 11.44M | 77.77M |
| Capital Expenditures | -1.08M | -1.14M | -1.37M | -605K | -473K | -648K | -2.2M | -2.17M | -132K | 0 |
| CapEx % of Revenue | 4.31% | 6.51% | 12.93% | 1.44% | 57.13% | 1506.98% | 8.27% | 5.88% | 0.33% | - |
| Acquisitions | 0 | 0 | 0 | 26.69M | 0 | 0 | 150.52M | 0 | 0 | 395K |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | -98.48M | 88.56M | -26.69M | 0 | 0 | -150.52M | 0 | 0 | 372K |
| Cash from Financing | 58.26M | 68.6M | 1.06M | 97.7M | 230.41M | 63.65M | 153.02M | 94.67M | 4.09M | -25.87M |
| Debt Issued (Net) | 0 | 0 | 0 | 4.88M | -313K | 18.34M | -272K | -262K | -2.23M | -26.13M |
| Equity Issued (Net) | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K | 1000K | 257K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 146K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | 105K | 452K | 1.06M | 664K | 3.7M | 2.22M | 2.4M | 1.4M | 542K | 0 |
| Net Change in Cash | 88.76M▲ 0% | -73.71M▼ 183.0% | 33.04M▲ 144.8% | 2.67M▼ 91.9% | 192.74M▲ 7127.0% | -76.99M▼ 139.9% | -49.06M▲ 36.3% | 45.68M▲ 193.1% | -66.81M▼ 246.3% | -22.48M▲ 0% |
| Free Cash Flow | 30.5M▲ 0% | -43.82M▼ 243.7% | -56.59M▼ 29.1% | -68.35M▼ 20.8% | -75.17M▼ 10.0% | -140.64M▼ 87.1% | -51.56M▲ 63.3% | -171.05M▼ 231.7% | -82.47M▲ 51.8% | -74.37M▲ 0% |
| FCF Margin % | 121.19% | -249.77% | -534.13% | -162.26% | -9078.38% | -327060.47% | -193.97% | -464.12% | -203.65% | -224.14% |
| FCF Growth % | 397.45% | -243.66% | -29.13% | -20.79% | -9.98% | -87.09% | 63.34% | -231.75% | 51.78% | 22.18% |
| FCF per Share | 43.59 | -48.63 | -61.42 | -39.29 | -30.56 | -49.81 | -13.76 | -36.83 | -16.83 | -16.83 |
| FCF Conversion (FCF/Net Income) | -2.31x | 1.10x | 0.86x | 2.40x | 0.85x | 0.82x | 0.24x | 0.98x | 1.19x | 1.06x |
| Interest Paid | 0 | 0 | 0 | 0 | 234K | 0 | 0 | 0 | 3.47M | 1.02M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 418K | 0 |
MRSN Key Ratios
Mersana Therapeutics, Inc. (MRSN) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | -538.53% | -163.11% | -64.76% | -57.47% | -97.22% | -191.03% | -266.24% | -505.14% | 183.15% |
| Return on Invested Capital (ROIC) | - | - | - | - | -1738.14% | - | - | - | - | 48.09% |
| Gross Margin | -27.16% | 94.71% | -465.56% | 100% | -7996.14% | 100% | 100% | 100% | 100% | 99.13% |
| Net Margin | -54.43% | -220.62% | -606.54% | -66.97% | -10633.45% | -395488.37% | -768.26% | -465.8% | -170.86% | -211.21% |
| Debt / Equity | - | - | - | 0.10x | 0.07x | 0.31x | 0.39x | 0.92x | - | -0.04x |
| Interest Coverage | - | - | - | -129.06x | -432.16x | -133.27x | -61.23x | -41.97x | -18.93x | -24.52x |
| FCF Conversion | -2.31x | 1.10x | 0.86x | 2.40x | 0.85x | 0.82x | 0.24x | 0.98x | 1.19x | 1.06x |
| Revenue Growth | 142.99% | -30.3% | -39.62% | 297.61% | -98.03% | -94.81% | 61716.28% | 38.65% | 9.88% | -4.76% |
MRSN SEC Filings & Documents
Mersana Therapeutics, Inc. (MRSN) SEC filings — annual & quarterly reports (10-K, 10-Q)
MRSN Frequently Asked Questions
Mersana Therapeutics, Inc. (MRSN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Mersana Therapeutics, Inc. (MRSN) reported $33.2M in revenue for fiscal year 2024. This represents a 220% increase from $10.4M in 2015.
Mersana Therapeutics, Inc. (MRSN) grew revenue by 9.9% over the past year. This is steady growth.
Mersana Therapeutics, Inc. (MRSN) reported a net loss of $70.1M for fiscal year 2024.
Dividend & Returns
Mersana Therapeutics, Inc. (MRSN) has a return on equity (ROE) of -505.1%. Negative ROE indicates the company is unprofitable.
Mersana Therapeutics, Inc. (MRSN) had negative free cash flow of $74.4M in fiscal year 2024, likely due to heavy capital investments.
Explore More MRSN
Mersana Therapeutics, Inc. (MRSN) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates